MedImmune announced that it has initiated a Phase 2 clinical trial in patients with chronic asthma to determine the safety of subcutaneous dosing of a humanized monoclonal antibody (MAb) that targets the interleukin-5 receptor (IL-5R).
[Sadece Üyeler Görebilir. Üye olmak için tiklayiniz...]